Major Adverse Effects Associated with Tacrolimus (Fk506) Based Regimen among Saudi Kidney Transplant Patients

被引:0
|
作者
Ali, Ahmed S. [1 ]
Al-Nasser, Marzog S. [2 ]
Sattar, Mai A. Abdul [1 ]
Alkreathy, Huda M. [1 ]
Al-Amma, Mohammed N. [3 ]
Alsulaimani, Rayan A. [1 ]
Abdulfattah, Ezz H. [4 ]
机构
[1] King Abdulaziz Univ, Fac Med, Dept Pharmacol, Jeddah, Saudi Arabia
[2] Armed Forces Hosp, Khamis Mushait, Southern Region, Saudi Arabia
[3] King Abdulaziz Univ, Fac Med, Dept Internal Med, Jeddah, Saudi Arabia
[4] King Abdulaziz Univ, Fac Sci, Dept Stat, Jeddah, Saudi Arabia
关键词
Tacrolimus; kidney transplant; side effects; therapeutic drug monitoring;
D O I
10.9734/JPRI/2018/41611
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tacrolimus (Fk506)- based immunosuppressant regimen has become the cornerstone in managing kidney transplant patients (KTP) , where it has been used typically used on chronic basis. However, various adverse effects on multiple organ systems are expected and their incidence is depending on many variables including genetic and non-genetic factors. The present study aims to explore the adverse effects associated with the chronic use of Tacrolimus - based immunosuppressant regimen in Saudi kidney transplant patients (SKTP). It was performed retrospectively at Kidney Transplant Center AFHSR in Khamis Mushait (Saudi Arabia) and comprised 100 SKTP treated with Tacrolimus who were followed-up for 24 months (2012-2014). The findings showed that the most common clinical complications associated with Tacrolimus based regimen were as follows: nephrotoxicity (46%), hypertension (27%), new onset diabetes mellitus (18%), infections (22%) hyperlipidemia (28%) and hypomagnesaemia (85%). In addition nausea and insomnia were shown to be other common complaints. Conclusion: The present study demonstrated a significant association between hypertension and chronic kidney rejection. as well as between nephrotoxicity and chronic rejection High trough levels of Tacrolimus were documented as a risk factor for the development of new onset diabetes mellitus (NODM) in SKTP.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] PHARMACOKINETICS OF TACROLIMUS (FK506) IN KIDNEY-TRANSPLANT PATIENTS
    MEKKI, Q
    LEE, C
    AWEEKA, F
    LASKOW, D
    NEYLAN, J
    MENDEZ, R
    STEINMULLER, D
    SCHECHTER, P
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (02) : 238 - 238
  • [2] Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients
    Gonschior, AK
    Christians, U
    Winkler, M
    Linck, A
    Baumann, J
    Sewing, KF
    [J]. CLINICAL CHEMISTRY, 1996, 42 (09) : 1426 - 1432
  • [3] PHARMACOKINETICS OF TACROLIMUS (FK506) IN LIVER-TRANSPLANT PATIENTS
    LEE, C
    JUSKO, W
    SHAEFER, M
    KLINTMALM, G
    HEBERT, M
    PIERGIES, A
    SCHECHTER, P
    MEKKI, Q
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (02) : 181 - 181
  • [4] Tacrolimus (FK506) pharmacokinetics in heart transplant patients.
    Sgrosso, JL
    Araujo, GL
    Fernandez, E
    Taborda, M
    Bergamo, S
    Vazquez, M
    [J]. TRANSPLANTATION, 2000, 69 (08) : S230 - S230
  • [5] Cyclosporine microemulsion (Neoral) versus tacrolimus (FK506) as maintenance therapy in kidney transplant patients
    Abou-Jaoude, MM
    Irani-Hakime, N
    Ghantous, I
    Najm, R
    Afif, C
    Almawi, WY
    [J]. TRANSPLANTATION PROCEEDINGS, 2003, 35 (07) : 2748 - 2749
  • [6] Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients
    Furth, S
    Neu, A
    Colombani, P
    Plotnick, L
    Turner, ME
    Fivush, B
    [J]. PEDIATRIC NEPHROLOGY, 1996, 10 (01) : 64 - 66
  • [7] PHARMACOKINETICS OF TACROLIMUS (FK506) IN BONE-MARROW TRANSPLANT PATIENTS
    MEKKI, QA
    PISCITELLI, D
    FITZSIMMONS, WE
    ARO, R
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 149 - 149
  • [8] POPULATION PHARMACOKINETICS OF TACROLIMUS (FK506) IN LIVER-TRANSPLANT PATIENTS
    MEKKI, QA
    LEE, C
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 162 - 162
  • [9] Pharmacokinetics of tacrolimus (FK506) in primary orthotopic heart transplant patients
    Undre, NA
    Meiser, BM
    Überfuhr, P
    Reichart, B
    Stevenson, P
    Schäfer, A
    Möller, A
    [J]. TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) : 1112 - 1115
  • [10] Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients
    Alak, AM
    Moy, S
    [J]. TRANSPLANTATION PROCEEDINGS, 1997, 29 (05) : 2487 - 2490